GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Unearned Income

Viracta Therapeutics (FRA:RYI) Unearned Income


View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Unearned Income?

Unearned Income only applies to banks.


Viracta Therapeutics (FRA:RYI) Business Description

Traded in Other Exchanges
Address
2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.